Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Travel Med ; 20(5): 278-82, 2013.
Article in English | MEDLINE | ID: mdl-23992569

ABSTRACT

BACKGROUND: Increasing numbers of travelers using immunosuppressive drugs visit hepatitis A endemic countries. Data on protection rates after hepatitis A vaccination in this group are scarce. METHODS: In this retrospective study, records of subjects with hepatitis A serology taken after vaccination were searched for in travel clinic databases. Relation between immunosuppressive drug use, age, gender, and time between vaccination and serology was evaluated. RESULTS: Seroprotection rates within 4 weeks after primary vaccination (50%) are lower than after 4 weeks (64%). After the complete series of two vaccinations seroprotection rates reach 95% although success depends on the immunosuppressive drug being used. Subjects under anti-TNF alpha treatment have significantly lower seroprotection rates than subjects using classical immunosuppressive drugs after the second vaccination. There is no influence of age or gender on seroprotection rates. CONCLUSIONS: Last-minute vaccination in subjects using immunosuppressive medication is not reliable, only 60% of our subjects had a protective antibody level after a single vaccination. When serology was done within 4 weeks after a single vaccination, seroprotection rates were only 50%, after 4 weeks this number rose to 64%. When persons visit a travel clinic in time for a complete vaccination series, satisfactory seroprotection rates can be reached. Seroprotection rate depends on the drug being used, persons using anti-TNF alpha are less protected.


Subject(s)
Hepatitis A Vaccines/therapeutic use , Hepatitis A , Immunocompromised Host , Immunosuppressive Agents , Travel , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Aged , Female , Hepatitis A/immunology , Hepatitis A/prevention & control , Hepatitis A Virus, Human/immunology , Humans , Immunocompromised Host/drug effects , Immunocompromised Host/immunology , Immunosuppression Therapy/methods , Immunosuppressive Agents/classification , Immunosuppressive Agents/therapeutic use , Logistic Models , Male , Middle Aged , Netherlands , Retrospective Studies , Risk Assessment/methods , Treatment Outcome , Vaccination/methods , Vaccination/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...